Sign In
Buy NVO
$47.42
+1.52 (+3.31%)
At Close: Jun 23, 2026
Novo VP Weighs In on Approval of Lilly's Obesity Pill
05:14pm, Wednesday, 01'st Apr 2026
Jamey Millar, executive vice president, US Operations of Novo Nordisk, reacts to Eli Lilly's once-daily weight-loss pill, called Foundayo, winning FDA approval on "Bloomberg The Close." -------- More
Pricing and availability of Novo, Lilly's weight-loss drugs
03:07pm, Wednesday, 01'st Apr 2026
The U.S. Food and Drug Administration has approved Eli Lilly's oral weight-loss drug, orforglipron, branded as Foundayo, making it the second pill to enter the fast-growing obesity treatment market.
Could This New Approval Be a Turning Point For Novo Nordisk?
02:00pm, Wednesday, 01'st Apr 2026
Novo Nordisk is launching a new, more effective version of Wegovy. Even with this new approval, the company likely won't catch up to its biggest competitor in the weight loss market.
The FDA approved Eli Lilly's new weight-loss pill, setting up a fight with rival Novo Nordisk over the next front in the booming market
11:38am, Wednesday, 01'st Apr 2026
The FDA go-ahead tees up a battle with rival Novo Nordisk over the next front in the booming weight-loss drug market.
NVO Launches Wegovy Subscription Plan, Boosts Access, Stock Up
11:16am, Wednesday, 01'st Apr 2026
Novo Nordisk stock jumps after launching a Wegovy subscription plan to cut costs, expand telehealth access and improve treatment adherence for sustained obesity care.
Novo Nordisk stock surges 4%: can NHS boost offset pricing pressure?
07:29am, Wednesday, 01'st Apr 2026
Novo Nordisk stock surged on Wednesday after a major policy win, which is seen as a turning point for the drugmaker. England's cost-effectiveness watchdog has backed broader use of Wegovy to cut the r
Novo Nordisk shares rise after Wegovy recommended by Britain's drug price regulator
04:47am, Wednesday, 01'st Apr 2026
Novo Nordisk weight loss drug Wegovy was recommended by England's drug price regulator to prevent heart attacks and strokes. The new recommendation from NICE will significantly expand access to Wegovy
British drug-cost watchdog recommends use of Novo's Wegovy to lower heart risks
07:05pm, Tuesday, 31'st Mar 2026
UK's drug cost-effectiveness watchdog has recommended Novo Nordisk's Wegovy to reduce the risk of serious heart problems or strokes in obese or overweight adults, becoming the first GLP-1 drug to b
Novo launches $249 Wegovy subscription, undercutting Lilly as shares fall 30%
04:23pm, Tuesday, 31'st Mar 2026
Novo Nordisk (NVO) is stepping up its push to regain share in the obesity drug market, introducing a subscription-based pricing model that could improve access
Lilly and Novo Show How AI Is Rewiring Big Pharma
02:45pm, Tuesday, 31'st Mar 2026
Eli Lilly and Novo Nordisk, the two companies that dominate the global market for GLP-1 weight loss and diabetes drugs, are each deploying artificial intelligence (AI) across different stages of drug
NVO Stock "Nothing Short of Disaster," Wegovy Subscription Program Lifts Shares
11:30am, Tuesday, 31'st Mar 2026
Novo Nordisk (NVO) shares continued to sink deeper into five-year lows on Monday as developments from Eli Lilly (LLY) outshine the Danish GLP-1 maker. On Tuesday, the company announced a multi-month s
Novo Nordisk Launches Discounted Subscription Program for Wegovy Obesity Drugs
08:33am, Tuesday, 31'st Mar 2026
The company is trying to win customers by offering a “lower, predictable monthly price” for its obesity drugs.
Through expanded collaboration with Novo Nordisk, eligible Med+ members can now save up to $1,200 per year on Wegovy®, increasing affordable access to FDA-approved GLP-1 treatment leveraging Weight W
Novo Nordisk launches multi-month subscriptions for Wegovy obesity drugs as it tries to catch up with Eli Lilly
07:39am, Tuesday, 31'st Mar 2026
Novo Nordisk launched a multi-month subscription program for its Wegovy obesity drug products that aims to ensure cash-paying patients pay lower, "predictable" monthly prices. Eligible patients can
Novo Nordisk to launch discounted Wegovy subscriptions for self-pay patients in US
07:34am, Tuesday, 31'st Mar 2026
Novo Nordisk will launch a discounted subscription plan for U.S. Wegovy patients paying for the drug themselves, offering monthly prices up to nearly 30% below its standard rate as it tries to wide
